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Detailed analysis of cytolytic T  lymphocytes (CTL)1 at the molecular level has been 
hampered by the cellular heterogeneity intrinsic to most model systems studied. The 
development of cloned lines (1, 2) of CTL facilitates both biochemical (3) and genetic 
(this report) analyses of function. 
CTL have been characterized  by a  distinctive  cell surface antigenic  profile that 
includes Thy-1, Lyt-2, and Lyt-3 (4). Several recent studies using alloantisera indicate 
that  antibodies  reactive with either Lyt-2 or Lyt-3, or with  the product  of a  close- 
linked  locus,  are able to block CTL activity in  the  absence of complement  (5,  6). 
Monoclonal antibodies directed against either Lyt-2 (7, 8)  or Lyt-3 (J. A. Ledbetter 
and L. A. Herzenberg, personal communication) also have been found to block CTL 
activity in the absence of complement. These data imply a  role for Lyt-2 and Lyt-3 
in cytolysis, but they cannot formally exclude that a  molecule required  for cytolytic 
activity merely is located near Lyt-2 and Lyt-3 on the cell surface. Antibody to Thy- 
1 does not block CTL activity in the absence of complement (7-9). 
To  investigate  the  role  of Lyt-2  and  Thy-1  in  cytolysis  from  an  independent 
approach,  we  have  generated,  and  analyzed  the  phenotypes  of,  variants  of  an 
especially lytic cloned CTL line (designated L3) which specifically lack either Lyt-2 
or  Thy-1.  An  analysis  of these  variants  indicates  that  neither  Lyt-2  nor  Lyt-3  is 
responsible for the lethal hit, but suggests that Lyt-2 and/or Lyt-3 are required for an 
antigen receptor functional in cytolysis. The data also suggest that the expression of 
Lyt-3 on the cell surface is  not  independent  of the expression of Lyt-2. Finally the 
data indicate that Thy-1 plays no role in cytolysis. 
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Materials and Methods 
Animals.  Adult female DBA/2 (H-2  a) mice were obtained either from The Jackson Labo- 
ratory  (Bar  Harbor,  Maine)  or  Laboratory Supply Co.  (Indianapolis, Ind.).  Adult  female 
C57BL/6  (H-2~ mice were obtained from The Jackson Laboratory. Adult female Lewis rats 
were obtained from Microbiological Associates (Walkersville, Md.). 
Culture Medium.  Dulbecco's modified Eagle's medium  (DMEM)  supplemented  with  2% 
heat-inactivated fetal calf serum  (FCS) (KC Biological, Inc., Lenexa, Kans.), 5 ×  10  -s M  2- 
mercaptoethanol  (2-ME),  10  mM  morpholinopropane-sulfonic acid (MOPS),  penicillin and 
streptomycin, and additional amino acids was used (10). 
Cloned CTL Line L3.  L3 is a cloned cytolytic T  cell line of C57BL/6  (H-2  b) origin having 
cytolytie activity specifically directed against H-2D  d (2). It has a normal karyotype and is Thy- 
1.2  +,  Lyt-l.2-, Lyt-2.2  +, and  Lyt-3.2  +  (2).  Both supernate  from  secondary mixed leukocyte 
culture (MLC)  (MLC SF) (or another lymphocyte growth factor) and irradiated spleen cells 
are required for proliferation (1). L3 has been maintained in culture for 2 yr with no discernible 
change in phenotype. 
L3 is passaged by transfer of 2 ×  104 cells (100 #1, 7-8 d after previous transfer) to 3-ml tissue 
culture wells (17-mm diameter; Linbro 24-well plate, 76-033-05;  Linbro Chemical Co., Ham- 
den, Conn.). Each well contained 6.5 X 106 irradiated (1,400 rad) (model 143 cesium irradiator; 
JLS  Shepherd  & Associates, Glendale, Calif.)  DBA/2 spleen cells and  33%  supernate from 
concanavalin A (Con A)-stimulated rat spleen cells, (LCA SF) in a final vol of 1.5 ml. Culture 
plates were then incubated in a 37°C 5% COz humidified incubator. 
Cloned Amplifier  T Lymphocyte Line L2.  L2 is a noncytolytic cloned M  locus (Mlsa)-reactive 
amplifier T  cell line of C57BL/6 origin. It is Thy-l.2  +, Lyt-l.2-, Lyt-2.2-, and Lyt-3.2-. The 
properties of L2 have been described in detail elsewhere (1, 2,  11). The protocol for passage of 
L2 is identical to that for L3, except that MLC SF is used in place of LCA SF. 
Production of Supernatant Fluids (SF).  The production of LCA SF and MLC SF have been 
described (2), but is briefly given here. (a) LCA SF: The supernate from a Con A  (2.5 #g/ml) 
(Pharmacia Fine Chemicals, Uppsala, Sweden) -stimulated culture of Lewis rat spleen cells was 
collected after 48 h.  (b) MLC SF: Secondary MLC were prepared by restimulating cells from 
primary C57BL/6 anti-DBA/2 MLC with irradiated DBA/2 spleen cells after 14 d of culture. 
After 48 h of culture, the supernate was collected. 
Antibodies.  The hybridoma antibodies AT83A (anti-Thy-l.2) (12),  2.43  (anti-Lyt-2.2) (7), 
3.200  (anti-Lyt-2)  (7),  and  3.155  (anti-Lyt-2)  (7)  have  been  described.  The  anti-Lyt-3.2 
hybridoma  antibody  53.5.1  was  kindly  provided  by  Dr.  J.  A.  Ledbetter  and  Dr.  L.  A. 
Herzenberg (Stanford University, School of Medicine, Palo Alto, Calif.) (13). 
Cell Variant Nomenclature.  The parental line is designated L3. The variants of L3 discussed 
here are designated L3:AT83A/1, L3:V4, L3:243/1, and L3:243/2; for convenience, the prefix 
"L3" will be dropped in subsequent references to the variants. 
Selection With Antibody and Complement.  Cells were incubated in the specified dilution of the 
antibody at room temperature for 30 rain. After centrifugation, they were resuspended in the 
specified dilution of rabbit complement and incubated for 45 min at 37°C. The cells were then 
washed three times before being returned to culture. 
Treatment With Mutagen.  Each of the variants described here was derived from one of three 
independent cultures treated with the mutagen ethyl methanesulfonate (EMS)  (Sigma Chem- 
ical Co., St. Louis, Mo.). The cultures were initiated with 2 ×  104 L3/well. 5 d later, when the 
cell density had reached 6 ×  l0  s L3/well, EMS was added to a final concentration of 150 #g/ 
ml. 34 h later, cells were washed three times with DMEM and returned to culture as described 
under Results. 
The cloning efficiency of the EMS-treated cells relative to those cells which had not been 
exposed to EMS was 47%. 
Quantitative Immunofluorescence.  The quantitation of the cell surface staining was performed 
using a  fluorescence-activated cell sorter  (FACS III; B-D  FACS Systems, Mountain  View, 
Calif.)  (14).  Debris was removed from  cell preparations before staining by Ficoll-Hypaque 
gradient centrifugation (15). For each histogram, 104 viable cells as detected by forward-angle 
light scattering (1 o_ 15 ° included angle) were analyzed (14). The fluorescence intensity units on 
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The procedure for indirect immunofluorescence staining of cells has been previously described 
(14). Hybridoma antibodies AT83A and 3.155 were coupled with biotin-suecinimide (Biosearch, 
San  Rafael, Ca.)  using the technique described by Bayer and Wilchek (16).  This permitted 
fluorescein-conjugated avidin (Vector Laboratories, Burlingame, Calif.) to be used as the second 
step in the indirect staining protocol. The second step for hybridoma antibody 53.5.1  was a 
fluorescein-conjugated rabbit anti-mouse Ig (17). For each stain, 106 cells were used and these 
were maintained at 0°C throughout the staining procedure. 
Assay for Cell-mediated Lympholysis (CML).  Cytolytic activity was measured as 51Cr release 
from labeled target cells. (a) To screen the microwells of a  cloning plate (6.4-ram diameter; 
Costar 3596; Costar, Data Packaging, Cambridge, Mass.) for specific cytolytic activity, such as 
was done to select for V4, a microcytotoxicity assay using 500 target cells was employed (18). 
(b)  The  conventional cytotoxicity assay using  5,000  target cells is essentially as previously 
described (19), except that centrifugation for 60 see at 200 g preceded the 3.5-h incubation at 
37°C. This assay was used to compare the cytolytic activity of the variants with that of L3. 
When either Con A or phytohemagglutin-P (PHA-P; Difco Laboratories, Detroit, Mich.) was 
used in conjunction with this assay, the final lectin concentration was 10 #g/ml. 
Assay for Anti-Lyt-2.2 (2. 43) Blocking of Cytolytic Activity in the Presence or Absence of Con A.  L3 
cells were treated either with monoclonal antibody 2.43  (anti-Lyt-2.2) or with  20%  FCS in 
DMEM for 30 min at 5°C. The cells were then assayed in a short-term 51Cr-release assay (7) for 
cytotoxicity against P-815 tumor target cells in the presence (10 #g/ml) or absence of Con A. 
EDTA (10 mM final concentration) was added after 30 min incubation with P-815 targets at 
37°C. Amount of 51Cr released into the supernate was determined at 2 h  (total) incubation. 
Targets.  P-815  is a  tumor cell line of DBA/2  (H-2  d)  origin. EL4  is a  tumor cell line of 
C57BL/6  (H-2  b) origin. AKR-A is a  tumor cell line of AKR (H-2  k) origin. These lines were 
maintained in tissue culture. 
Results 
Derivation of Variant V4.  After treatment with EMS for 34 h, trypan blue analysis 
indicated an average of 1.5 ×  106 cells/well for two wells not exposed to EMS and an 
average of 8.5  ×  105 cells/well for two wells exposed to EMS.  Cells from these wells 
were cultured at limiting-dilution to determine the relative cloning efficiency of the 
EMS-treated  cells.  10  d  after  initiating  the  culture,  microwells  were  scored  for 
proliferating cells and  then  tested  for specific lysis of P-815  in  a  microcytotoxicity 
assay.  V4  was  selected  as  a  well  from  the  EMS-treated  group  that  contained 
proliferating cells that had no demonstrable specific killing. For the particular dilution 
which yielded V4, 9 of 16 of the wells had proliferating cells. 
Derivation of Variants 243/1 and 243/2.  32 wells that contained L3 cells were treated 
with EMS as described in Materials and Methods.  12 d after treatment, during which 
time the cultures were  divided twice, the cells were  harvested  (12  ×  106  total)  and 
treated with 2.0 ml of undiluted hybridoma culture supernate 2.43 followed by 1.0 ml 
of a  1:5 dilution of rabbit complement. Trypan blue analysis indicated 97%  killing. 
The surviving cells were placed in culture for eight days, after which this population 
(comprised of 1 ×  10  n cells) was again treated with  2.5  ml of undiluted  hybridoma 
culture supernate  2.43  followed by  1.0  ml  of a  1:5  dilution of rabbit  complement. 
Trypan blue analysis indicated 95% killing. The treated cells were then transferred to 
72 wells of a  cloning plate. Thirteen  days later, 2 of 72 microwells were positive for 
growth. These two proliferating lines were designated 243/1 and 243/2. The estimated 
mutation frequency was 3  ×  10  -7. 
Derivation of  Variant AT83A/1.  Another  32  wells  that  contained  L3  cells  were 
treated  with  EMS  as  described  in  Materials  and  Methods.  12  d  after  treatment, 
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total)  and  treated with  2.0  ml  of a  1:20  dilution  of hybridoma culture supernate 
AT83A  followed by  1.0  ml  of a  1:5  dilution  of rabbit  complement.  Trypan  blue 
analysis indicated 95% killing. The surviving cells were placed in culture for 8 d, after 
which this population (comprised of 3 ×  106 cells) was again treated with 6.0 ml of a 
1:20  dilution of hybridoma culture supernate AT83A  followed by  1.0  ml  of a  1:5 
dilution  of rabbit  complement.  Trypan blue analysis  indicated  100%  killing.  The 
treated cells were then transferred to 72 wells of a cloning plate.  13 d  later,  13 of 72 
microwells were positive for growth. These thirteen proliferating lines were pooled 
and placed in culture for 7 d, after which one-half of this population (12 ×  106 cells) 
was treated with  12.0 ml of a  1:20 dilution of hybridoma culture supernate AT83A 
followed by 2.5  ml  of a  1:5  dilution  of rabbit  complement.  Trypan blue analysis 
indicated 60% killing. AT83A/1 was established from an aliquot of the surviving cells. 
The estimated mutation frequency was  1 ×  10 -6. 
FACS analysis (Fig.  1) and subsequent antibody-and-complement-mediated ~lCr- 
release assays, using monoclonal antibody AT83A, over a  period of 2 months (data 
not shown) suggest that AT83A/1 represents a uniformly Thy-1- population of cells. 
AT83A/1 is currently being cloned. 
Surface Phenotype of the Variants.  The surface phenotype of the variants was initially 
probed  using  an  antibody-and-complement-mediated  51Cr-release  assay  (data  not 
shown). Monoclonal antibodies AT83A, 2.43, and 3.200 were used. The parental line 
L3 was lysed by each of these antibodies. On the other hand, AT83A/1 was found to 
be  specifically  insensitive  to  AT83A.  V4,  243/1,  and  243/2  were  found  to  be 
specifically insensitive  to  2.43  and  3.200.  At  the  level  of this  assay,  therefore,  it 
appeared that lines had been derived which had lost specifically either Thy-1 or Lyt- 
2. 
A  more rigorous analysis of the surface phenotype was provided by quantitative 
fluorescence using the FACS. Such an analysis is shown in Figs.  1, 2, and 3. The cells 
were stained with hybridoma antibodies recognizing either Thy-1.2, Lyt-2, or Lyt-3.2. 
From  Fig.  1,  it  is  apparent  that  anti-Thy-l.2  stained  L3,  but  did  not  stain 
AT83A/1. The patterns of reactivity for V4, 243/1, and 243/2 with anti-Thy-1.2 were 
comparable to that for L3 (data not shown). 
The quantitation of the cell surface expression of Lyt-2 by the parental line L3 and 
the variant  lines derived from it is shown  in  Fig.  2.  It  is apparent  that  anti-Lyt-2 
stained L3, but did not react with the amplifier line L2 which had previously been 
1 
r  I  I  I  I 
0  5  I0  15  20 
Fluorescence  intensity 
(arbitrary  units) 
Fla.  1.  Expression of cell surface Thy-l.2. Variant AT83A/1 was derived from L3 as described in 
Results. Incubation of cells with biotin-succinimide-coupled monoclonal antibody AT83A  (anti- 
Thy-l.2) was followed by staining with fluorescein-conjugated avidin. The FACS III was used to 
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FIG. 2.  Expression  of cell surface Lyt-2. Variants AT83A/1, V4, 243/l, and 243/2 were derived 
from L3 as described in Results. L2 is a noncytolytic  cloned amplifier T lymphocyte line. Incubation 
of cells with biotin-succinimide coupled monoclonal antibody 3.155 (anti-Lyt-2) was followed by 
staining with fluorescein-conjugated  avidin. The FACS III was used to quantify the immunoflu- 
orescent staining. 
o 
E 
SL. 
L2 
' 
V4 
243/f 
245/2 
0  I  2  3  4  0  I  2  3  4  S 
Fluorescence  intensity  (arbitrary  units) 
FxG. 3.  Expression  of cell surface Lyt-3.2. Variants AT83A/1, V4, 243/1, and 243/2 were derived 
from L3 as described in Results. L2 is a noncytolytic  cloned amplifier T lymphocyte  line. Incubation 
of cells with monoclonal antibody 53.5.1 (anti-Lyt-3.2) was followed by staining with fluorescein- 
conjugated rabbit  anti-mouse Ig.  The  FACS III was  used to  quantify the  immunofluorescent 
staining. 
shown to be Lyt-2- (2). The pattern of reactivity for AT83A/1 was comparable to 
that for L3. On the other hand, the staining profile for V4 was comparable to that for 
L2; that is, anti-Lyt-2 did not react with V4.  243/1  and 243/2 bound slightly more 
anti-Lyt-2 than did either L2 or V4. From the intensity of fluorescence, the amount 
of Lyt-2 on the surface of 243/1  and 243/2 was estimated to be <10% of that found 
on the surface of the parental line L3. 
From Fig. 3, it is apparent that results obtained with anti-Lyt-3.2 mirrored those 
obtained with anti-Lyt-2 for all cell lines tested. The parental line L3 was positive, 
whereas  L2  and V4  did not bind the  anti-Lyt-3.2. Lines 243/1  and 243/2  showed 
fluorescence slightly above background, but exhibited < 10% of the cell surface Lyt- 
3.2 expressed on L3. 600  Lyt-2-/Lyt-3-  VARIANTS  OF  A  CLONED  CYTOLYTIC  T  CELL  LINE 
Cytolytic Activity  of the  Variants.  The parental line L3 specifically lyses targets that 
express H-2D  d alloantigen  (2);  however,  it  can  be  made  to  lyse irrelevant  targets 
(those not expressing H-2D  a)  by the appropriate concentration of either Con  A  or 
PHA-P. These lectins have been shown to allow the expression of cytolytic activity in 
the absence of a specific receptor-antigen interaction (20). 
The cytolytic activity of AT83A/1  is similar to that of the parental line L3 (data 
not shown). It specifically lyses' P-815 (H-2  d) target cells as efficiently as does L3. The 
irrelevant targets EL4 (H-2  b)  and AKR-A  (H-2  k)  are lysed only in the presence of 
Con A or PHA-P. 
The behavior of variant V4 is very different from that of L3 in that it appears to 
have  lost  the  capacity  to  recognize  the  appropriate  antigen.  Specifically,  in  the 
absence of Con A, V4 lyses the relevant target P-815 at least  100 times less efficiently 
than does the parental line L3 (Fig. 4). However, in the presence of Con A, the lytic 
activity against P-815 is comparable to that of L3. Apparently the intrinsic cytolytic 
activity of V4  is  comparable  to  that  of L3,  but  V4  is  defective in  directing  this 
cytolytic activity to the appropriate target. V4 lyses the irrelevant targets EL4 and 
AKR-A only in the presence of Con A or PHA-P (data not shown). 
The behavior of variant 243/1  is similar in general to that of V4 in that it too is 
defective in lysing the relevant target P-815. However, in the presence of Con A, the 
lytic activity of 243/1 against P-815 is much less than that of L3 and V4 (Fig. 5). The 
behavior of 243/2 is essentially identical to that of 243/1. The basis for this difference 
between variant V4 and variants 243/1 and 243/2 has not yet been determined, hut 
it indicates that line V4 is not identical to the lines 243/1 and 243/2. 
Blocking  of L3  Cytolytic  Activity  by  Monoclonal  Antibody  2.43  (Anti-Lyt-2.2)  Can  be 
Circumvented by Inclusion of Con A  in the Assay.  Monoclonal antibody 2.43 blocks the 
cytolytic activity of L3 against the relevant target P-815 in the absence of complement 
(7).  It was of interest to examine whether this blocking is observed when Con A  is 
included  in  the  assay.  The  results  given  in  Fig.  6  indicate  that  it  is  not.  Con  A- 
mediated lysis of the irrelevant target EL4 by L3 also is not blocked by antibody 2.43 
(data not shown). Antibody 2.43 therefore appears to block receptor-mediated, but 
not lectin- (Con A) mediated, cytolysis by L3. 
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FIG.  4.  Cytolytic activity of variant V4 (El) compared with that of parent  L3 (O). Cytolysis was 
measured in  a  3.5-h 5'Cr-release assay with  P-815  tumor  target  cells, with  (...)  (10 /~g/ml)  or 
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Fro,  5.  Cytotytic activity of variant 243/l  (A) compared with that of parent L3 (0). Cytolysis was 
measured in  a  3.5-h 5]Cr-release  assay with  P-815  tumor  target  cells, with  (...)  (10 #g/ml)  or 
without (--) Con A. 
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FiG,  6.  Blocking  of L3  cytolytic  activity  by  monoclonal  antibody  2.43  (anti-Lyt-2.2)  can  be 
circumvented by inclusion of Con A  in the assay. L3 ceils were treated either with antibody 2.43 
(O)  or with medium alone (0) and then assayed in a short-term ~lCr-release assay for cytotoxicity 
against P-815 tumor targets in the presence (...)  (10 #g/ml) or absence (--) of Con A. 
Discussion 
To investigate the role of Lyt-2 and Thy-1  in cytolysis, we have generated, and 
characterized the cytolytic activity of, variants of the cloned CTL parental line L3 
that specifically lack either Lyt-2 or Thy- 1. Collectively, the data indicate that neither 
Lyt-2 nor Lyt-3 is required for the lethal hit, but suggest that Lyt-2 and/or Lyt-3 are 
required to direct this lethal hit to the appropriate target. The data also suggest that 
the expression of Lyt-3 on the cell surface is not independent of the expression of Lyt- 
2. The results also indicate that Thy-1 is not required for cytolysis. Finally, the data 
presented  here  demonstrate  the  feasibility of analyzing CTL  function by  genetic 
manipulation of cell lines derived by the procedure used for L3. These points will be 
expanded upon below. 
Variant AT83A/1 has no detectable Thy-1 on its surface. At this point, it is unclear 
which  of the  complementation  classes  of Thy-1-  mutants  is/are  represented  by 
AT83A/1  (21).  In  any case,  these cells lyse P-815  specifically as  well  as  does the 
parental line L3. This indicates that Thy-1 is not required for cytolysis. 
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types is unclear, although biochemical (3) and genetic analyses should be informative. 
Specifically, it is unclear how pleiotropic the mutations are. However, it is important 
to note that the Thy-1- line expresses Lyt-2 and Lyt-3, and the Lyt-2-/Lyt-3- lines 
express Thy-1. Thus, expression of one set  of cell surface antigens characteristic of 
subpopulations of T  lymphocytes is not linked to expression of another cell surface 
antigen characteristic of all T  lymphocytes. Also, FACS analysis using monoclonal 
antibodies indicates that V4 and L3 express to a comparable extent both T200 and 
another high-molecular-weight antigen which is present on activated T  lymphocytes 
(M. Sarmiento, manuscript in preparation). Finally it is important to note that the 
retention of specific killing activity by the Thy-1- line indicates that the loss of specific 
cytolytic activity by the Lyt-2-/Lyt-3- lines is not a  result of a  nonspecific effect of 
EMS mutagenesis. 
Previous observations that anti-Lyt-2 and anti-Lyt-3 antibodies block CTL activity 
in the absence of complement did not resolve whether the effect of antibody was on 
the recognition or the  lethal hit  stage of cell-mediated cytolysis. The variant  cells 
provide discriminating  evidence. Variant  V4  demonstrates  that  the cytolytic defi- 
ciency  of  a  Lyt-2-/Lyt-3-  CTL  variant  can  be  entirely  circumvented  through 
employment of conditions  (lectins)  that  do  not  require a  specific receptor-antigen 
interaction. This places any role of Lyt-2/Lyt-3 in cytolysis before the lethal hit, in 
the recognition stage (22). The concomitant loss of specific killing and the Lyt-2/Lyt- 
3 molecule(s) by at least two independent variant lines, selected for on the basis of 
different criteria, strengthens this interpretation. So does the observation that mono- 
clonal anti-Lyt-2.2 antibody in the absence of complement blocks receptor-mediated, 
but not Con A-mediated, cytolysis by L3. Taken together, these data argue strongly 
that Lyt-2 and/or Lyt-3 are required for an antigen receptor functional in cytolysis. 
Supporting this interpretation are preliminary investigations of conjugate formation 
by the method of Glasebrook (23), which suggest that whereas L3 and AT83A/1 form 
conjugates with P-815 with comparable efficiency, V4 does not form conjugates (D. 
P. Dialynas, unpublished observations). The less efficient lectin-mediated cytolysis by 
243/1 and 243/2 relative to that by V4 may be a result of the lesion(s) of the former 
extending either to a deficiency of the appropriate carbohydrate on the cell surface or 
to a functional loss of unidentified other component(s) required for cytolysis. 
The  results  given  here also  indicate  that  at  last  two  independent  variant  lines 
concomitantly lost both Lyt-2 and Lyt-3. In the case of 243/1  and  243/2, selection 
with anti-Lyt-2 monoclonal antibody and complement resulted in the loss of Lyt-3 
but not of the other unselected marker Thy-1. Recent FACS analyses using mono- 
clonal antibodies indicate that  the parental  line L3 expresses the same number of 
Lyt-2  and  Lyt-3  determinants  on  the  cell  surface  (J.  A.  Ledbetter  and  L.  A. 
Herzenberg, personal communication). Collectively these data argue forcefully for a 
model  in  which  the expression of Lyt-3 on  the cell surface is  in  some way tightly 
coupled to the expression of Lyt-2 on the cell surface. This is compatible with recent 
speculation, arising out of an analysis of the structures recognized by anti-Lyt-2 and 
anti-Lyt-3 antibodies, that either the Lyt-2 and Lyt-3 determinants exist on the same 
molecule or the Lyt-2 and Lyt-3 molecules are associated as a dimeric complex (24, 
25). 
The results presented here suggest a model (5, 8) in which Lyt-2/Lyt-3 corresponds 
to a constant domain of the antigen receptor on the parental line L3. However, the D.  DIALYNAS, M.  LOKEN,  A. GLASEBROOK,  AND F.  FITCH  603 
data cannot discriminate between a  model in which the receptor specificity informa- 
tion  is  associated  with  the  Lyt-2/Lyt-3 molecule(s)  or one in which  it  is  associated 
with  another,  independent  molecule on the cell  surface  (in which case  Lyt-2/Lyt-3 
might serve to efficiently couple antigen recognition with cytolysis). The Lyt-2-/Lyt- 
3-  variant  lines  described  here,  particularly  V4,  should  facilitate  experiments  that 
address this question. 
Summary 
To investigate the role of Lyt-2 and Thy- 1 in cytolysis, we have generated, by ethyl 
methanesulfonate  mutagenesis  and  selection,  variants  of  the  cloned  cytolytic  T 
lymphocyte line L3 that specifically lack either Lyt-2 or Thy- 1. An analysis of these 
variants  indicates  that  neither  Lyt-2 nor Lyt-3 is  responsible  for the  lethal  hit,  but 
suggests that  Lyt-2 and/or  Lyt-3 are required  for an antigen  receptor functional  in 
cytolysis. The data also suggest that the expression of Lyt-3 on the cell surface is not 
independent of the expression of Lyt-2. Finally the data indicate that Thy- 1 plays no 
role in cytolysis. 
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